Leave Your Message
Company News

Company News

News Categories
Featured News
recommended service
quick links
A pH-Tunable Thiourea Bridge Opens New Doors in Cyclic Peptide Drug Discovery

A pH-Tunable Thiourea Bridge Opens New Doors in Cyclic Peptide Drug Discovery

2026-06-11

A pH-switchable thiourea cyclization is used for generating structurally diverse cyclic peptide libraries, enabling the discovery of potent and stable binders against challenging protein-protein inter

view detail
CD19 CAR-T Therapy Achieves Triple Remission in Refractory Autoimmune Diseases

CD19 CAR-T Therapy Achieves Triple Remission in Refractory Autoimmune Diseases

2026-05-25

This article demonstrates that a single infusion of CD19 CAR-T cells can achieve simultaneous, drug-free remission of three refractory autoimmune diseases by resetting the B cell compartment.

view detail
Literature Analysis (Science) | Breaking the Central Dogma: The Discovery of Protein-Templated DNA Synthesis

Literature Analysis (Science) | Breaking the Central Dogma: The Discovery of Protein-Templated DNA Synthesis

2026-05-14

This discovery overturns the Central Dogma by demonstrating that proteins can serve as direct templates for sequence-specific DNA synthesis, fundamentally redefining the flow of genetic information.

view detail
Literature Analysis (Nature) | Evo 2 Technical Analysis Decoding the Blueprint of Life with AI

Literature Analysis (Nature) | Evo 2 Technical Analysis Decoding the Blueprint of Life with AI

2026-04-22

Alpha Lifetech offers specialized CRO services in Phage Display-based Antibody Discovery - including VHH, Fab, scFv, Aptamer, and Peptide development.

view detail
SCIENCE Literature Analysis (IF = 45.8) | CAR-A for Alzheimer’s: A Next-Generation Neuro-Immunotherapy Approach

SCIENCE Literature Analysis (IF = 45.8) | CAR-A for Alzheimer’s: A Next-Generation Neuro-Immunotherapy Approach

2026-04-06

Alpha Lifetech provides high stability, conformation specific molecular entities (including VHH, Fab, and scFv), paired with CRO services from phage display discovery to CAR functional validation.

view detail
Literature Analysis (IF = 10.5) | Bridging the Gap in NSCLC Therapy: The Rise of Antibody-Drug Conjugates

Literature Analysis (IF = 10.5) | Bridging the Gap in NSCLC Therapy: The Rise of Antibody-Drug Conjugates

2026-03-16

Alpha Lifetech provides a comprehensive and fully integrated Antibody Discovery Platform to generate high-affinity, highly specific antibodies, accelerating your ADC development.

view detail
Literature Analysis (IF = 21.7) | Unlocking the Black Box: Mechanisms of Resistance in Next-Generation Antibody-Drug Conjugates

Literature Analysis (IF = 21.7) | Unlocking the Black Box: Mechanisms of Resistance in Next-Generation Antibody-Drug Conjugates

2026-02-09
Alpha Lifetech’s high-affinity, highly specific antibodies serve as ideal targeting components for Antibody-Drug Conjugates (ADCs), directly accelerating your ADC development.
view detail
India Reports Nipah Virus Outbreak: What is Nipah Virus?

India Reports Nipah Virus Outbreak: What is Nipah Virus?

2026-01-27

Alpha Lifetech has established a mature and robust Antibody Discovery Platform to accelerate drug discovery pipeline.

view detail
Literature Analysis (IF 10.3) | A Deep Dive into Phage Display-Driven Antibody Engineering

Literature Analysis (IF 10.3) | A Deep Dive into Phage Display-Driven Antibody Engineering

2026-01-26

Alpha Lifetech’s Antibody Discovery services delivering highly specific VHH, scFv and Fab antibodies with superior affinity by Phage Display Technology.

view detail
Literature Analysis (IF 45.8) | Relationship Between CAR-T Therapy and Bispecific Antibodies

Literature Analysis (IF 45.8) | Relationship Between CAR-T Therapy and Bispecific Antibodies

2025-12-31

Alpha Lifetech has extensive expertise in peptide library construction and screening services. In addition to our existing peptide libraries, we offer peptide library design and screening services.

view detail